GlassScriptPhysician profile
Anindya K Sen
NPI 1164471207
$7,323.89
in general payments reported to CMS, 2019-2025
41 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,490 · 2020: $1,288 · 2021: $1,169 · 2022: $1,660 · 2023: $874 · 2024: $573 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,451.13 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,062.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $742.60 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $492.19 | 2019-2022 | |
| Pfizer INC. | $383.09 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $361.61 | 2019-2023 | Xarelto |
| Abbott Laboratories | $273.83 | 2021-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $259.50 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $230.25 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $224.83 | 2019-2022 | |
| Amgen INC. | $211.20 | 2019-2023 | Repatha |
| Amarin Pharma, INC. | $167.01 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $129.28 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $104.78 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anindya Sen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.